Efficacy of drugs in chronic idiopathic constipation: a systematic review and network meta-analysis.

Published on Nov 1, 2019in The Lancet Gastroenterology & Hepatology14.789
· DOI :10.1016/S2468-1253(19)30246-8
Pavit Luthra1
Estimated H-index: 1
(Royal Free Hospital),
Michael Camilleri146
Estimated H-index: 146
(Mayo Clinic)
+ 3 AuthorsAlexander C. Ford86
Estimated H-index: 86
(University of Leeds)
Sources
Abstract
Summary Background There are several drugs available for the treatment of chronic idiopathic constipation, but their relative efficacy is unclear because there have been no head-to-head randomised controlled trials. We did a network meta-analysis to compare the efficacy of these therapies in patients with chronic idiopathic constipation. Methods We searched Medline, Embase, Embase Classic, and the Cochrane Central Register of Controlled Trials for randomised controlled trials published from inception to week 3 June, 2019, to identify randomised controlled trials assessing the efficacy of drugs (osmotic or stimulant laxatives, elobixibat, linaclotide, lubiprostone, mizagliflozin, naronapride, plecanatide, prucalopride, tegaserod, tenapanor, or velusetrag) in adults with chronic idiopathic constipation. Participants had to be treated for a minimum of 4 weeks, and we extracted data for all endpoints preferentially at 4 weeks, 12 weeks, or both. Trials included in the analysis reported a dichotomous assessment of overall response to therapy (response or no response to therapy). We pooled the data using a random effects model, and reported efficacy and safety of all treatments as a pooled relative risk (RR) with 95% CIs to summarise the effect of each comparison tested. To rank treatments, we used P-scores, which measure the extent of certainty that a treatment is better than another treatment, averaged over all competing treatments. Findings We identified 33 eligible randomised controlled trials of drugs, comprising 17 214 patients. Based on an endpoint of failure to achieve three or more complete spontaneous bowel movements (CSBMs) per week, the stimulant diphenyl methane laxatives bisacodyl and sodium picosulfate, at a dose of 10 mg once daily, were ranked first at 4 weeks (RR 0·55, 95% CI 0·48–0·63, P-score 0·99), and prucalopride 2 mg once daily ranked first at 12 weeks (0·82, 0·78–0·86, P-score 0·96). When response to therapy was defined as falilure to achieve an increase of one or more CSBM per week from baseline, diphenyl methane laxatives at a dose of 10 mg once daily ranked first at 4 weeks (0·44, 0·37–0·54, P-score 0·99), with prucalopride 4 mg once daily ranked first at 12 weeks (0·74, 0·66–0·83, P-score 0·79), although linaclotide 290 μg once daily and prucalopride 2 mg once daily had similar efficacy (P-scores of 0·76 and 0·71, respectively). Bisacodyl ranked last in terms of safety for total number of adverse events and abdominal pain (P-score 0·08). Interpretation Almost all drugs studied were superior to placebo, according to either failure to achieve three or more CSBMs per week or or failure to achieve an increase of one or more CSBM per week over baseline. Although diphenyl methane laxatives ranked first at 4 weeks, patients with milder symptoms might have been included in these trials. Prucalopride ranked first at 12 weeks, and many of the included trials recruited patients who previously did not respond to laxatives, suggesting that this drug is likely to be the most efficacious for patients with chronic idiopathic constipation. However, because treatment duration in most trials was 4–12 weeks, the long-term relative efficacy of these drugs is unknown. Funding None.
📖 Papers frequently viewed together
1 Citations
90 Citations
54 Citations
References62
Newest
For decades, chronic idiopathic constipation (CIC) has been one of the most common chronic functional gastrointestinal disorders encountered by clinicians. Common comorbidities include depression, diabetes, functional dyspepsia, hypothyroidism, overweight, obesity, and neurological disorders. CIC imposes a large economic burden on the American healthcare system with estimated costs of 1912 to 522 in 2007 US dollars per patient per year. Individuals affected by CIC indicate significant rates o...
4 Citations
#1Shin Fukudo (Tohoku University)H-Index: 54
#2Hiroto Miwa (Hyogo College of Medicine)H-Index: 54
Last. Toshifumi Ohkusa (Jikei University School of Medicine)H-Index: 43
view all 11 authors...
BACKGROUND: A previous phase II dose-ranging study of linaclotide in a Japanese chronic constipation (CC) population showed that 0.5 mg was the most effective dose. This study aimed to verify the hypothesis that 0.5 mg of linaclotide is effective and safe in Japanese CC patients. METHODS: This was a Japanese phase III randomized, double-blind, placebo-controlled (part 1), and long-term, open-label extension (part 2) study of linaclotide. CC patients (n = 186) diagnosed using the Rome III criteri...
9 CitationsSource
#1Shin Fukudo (Tohoku University)H-Index: 54
#2Yuka Endo (Tohoku University)H-Index: 11
Last. Hiroaki TanakaH-Index: 47
view all 35 authors...
Summary Background Mizagliflozin is a novel oral sodium-glucose cotransporter 1 (SGLT1) inhibitor that increases luminal glucose and water. This study assessed the efficacy and safety of mizagliflozin in patients with functional constipation. Methods In this multicentre, randomised, double-blind phase 2 trial at 32 hospitals and community outpatient clinics in Japan, we enrolled patients with functional constipation or constipation-predominant irritable bowel syndrome, aged 20 years or older. Pa...
15 CitationsSource
#1Atsushi Nakajima (YCU: Yokohama City University)H-Index: 82
#2Mitsunori SekiH-Index: 2
Last. Michael Camilleri (Mayo Clinic)H-Index: 146
view all 7 authors...
Summary Background A subset of patients with constipation has reduced colonic bile acid concentrations, which are associated with slow colonic transit. In a previous study, elobixibat, a locally acting ileal bile acid transporter inhibitor, accelerated colonic transit in Japanese patients with functional constipation. In this study, we aimed to determine the efficacy of elobixibat for short-term treatment of chronic constipation, and safety, patient satisfaction, and quality of life with long-te...
53 CitationsSource
#1Atsushi Nakajima (YCU: Yokohama City University)H-Index: 82
#2Mitsunori SekiH-Index: 2
Last. Shinya TaniguchiH-Index: 3
view all 3 authors...
Background Elobixibat is an oral treatment candidate for chronic constipation with a novel mechanism of action via inhibition of the ileal bile acid transporter. We performed this randomized, double-blind, placebo-controlled, dose-finding phase IIb study in Japanese patients with chronic constipation to determine the optimal clinical dose of elobixibat.
31 CitationsSource
#1Philip Schoenfeld (VA: United States Department of Veterans Affairs)H-Index: 1
#2Brian E. Lacy (Dartmouth–Hitchcock Medical Center)H-Index: 54
Last. Michael HallH-Index: 4
view all 14 authors...
Low-Dose Linaclotide (72 μg) for Chronic Idiopathic Constipation: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial
27 CitationsSource
Background:Plecanatide, with the exception of a single amino acid replacement, is identical to human uroguanylin and is approved in the United States for adults with chronic idiopathic constipation (CIC). This double-blind, placebo-controlled, phase III study evaluated the efficacy and safety of plecanatide versus placebo in CIC.Methods:Adults meeting modified Rome III CIC criteria were randomized to plecanatide 3 mg (n = 443), 6 mg (n = 449), or placebo (n = 445). Patients recorded bowel moveme...
31 CitationsSource
#1Alfred D. Nelson (Mayo Clinic)H-Index: 10
#2Michael Camilleri (Mayo Clinic)H-Index: 146
Last. M. Hassan Murad (Mayo Clinic)H-Index: 88
view all 9 authors...
Objective To compare efficacy of pharmacotherapies for chronic idiopathic constipation (CIC) based on comparisons to placebo using Bayesian network meta-analysis. Data sources We conducted searches (inception to May 2015) of MEDLINE, EMBASE, Scopus and Cochrane Central, as well as original data from authors or drug companies for the medications used for CIC. Study selection Phase IIB and phase III randomised, placebo-controlled trials (RCT) of ≥4 weeks9 treatment for CIC in adults with Rome II o...
74 CitationsSource
#1Toshihiro InoueH-Index: 2
#2Masaaki TakemuraH-Index: 1
Last. Masayuki IsajiH-Index: 13
view all 11 authors...
Chronic constipation is a highly common functional gastrointestinal disorder that adversely affects patient quality of life. At present, limited therapeutic options are available for the treatment of chronic constipation, which indicates the need for new therapeutic agents. Herein, we report the potential of mizagliflozin, a novel selective sodium glucose co-transporter 1 (SGLT1) inhibitor, for the amelioration of chronic constipation. Mizagliflozin's inhibitory activity against SGLTs was evalua...
15 CitationsSource
#1Susanne Johansson (AstraZeneca)H-Index: 12
#2David P. RosenbaumH-Index: 6
Last. Maria Leonsson-Zachrisson (AstraZeneca)H-Index: 12
view all 4 authors...
Background Tenapanor (RDX5791, AZD1722), a small molecule with minimal systemic availability, is an inhibitor of the sodium/hydrogen exchanger isoform 3 (NHE3). Tenapanor acts locally in the gut to reduce absorption of sodium and phosphate. It is being developed for the treatment of patients with hyperphosphatemia in CKD requiring dialysis and patients with constipation-predominant irritable bowel syndrome. We report the safety, pharmacodynamics, and pharmacokinetics of tenapanor in Japanese vol...
25 CitationsSource
Cited By31
Newest
#1Eric D. Shah (Dartmouth College)H-Index: 8
#2Kyle Staller (Harvard University)H-Index: 13
Last. William D. CheyH-Index: 78
view all 9 authors...
INTRODUCTION Chronic idiopathic constipation (CIC) is a common and burdensome illness. We performed a cost-effectiveness analysis of the US Food and Drug Administration-approved CIC drugs to evaluate and quantify treatment preferences compared with usual care from insurer and patient perspectives. METHODS We evaluated the subset of patients with CIC and documented failure of over-the-counter (OTC) osmotic or bulk-forming laxatives. A RAND/UCLA consensus panel of 8 neurogastroenterologists inform...
Source
#1Brigida Barberio (UNIPD: University of Padua)H-Index: 7
#2Ciaran Judge (St James's University Hospital)H-Index: 1
Last. Alexander C. Ford (University of Leeds)H-Index: 86
view all 4 authors...
Summary null Background null Functional constipation is a common functional bowel disorder in the community, which has a varying prevalence across cross-sectional surveys. We did a contemporaneous systematic review and meta-analysis of studies using comparable methodology and all iterations of the Rome criteria to estimate the global prevalence of functional constipation. null Methods null In this systematic review and meta-analysis, we searched MEDLINE, Embase, and Embase Classic from Jan 1, 19...
1 CitationsSource
Source
#1Cyriac Abby Philips (Center for Excellence in Education)
#2Libin AbrahamH-Index: 13
view all 2 authors...
Source
#1Vivek C. Goodoory (St James's University Hospital)
#1Vivek C. Goodoory (St James's University Hospital)
Last. Alexander C. Ford (St James's University Hospital)H-Index: 86
view all 3 authors...
1 CitationsSource
#1Xiaolin LiuH-Index: 1
#2Min Dai (Nanjing Medical University)H-Index: 4
Last. Jun WangH-Index: 210
view all 13 authors...
Abstract The human gut microbiome has primarily been studied through the use of fecal samples, a practice that has generated vital knowledge on the composition and functional capacities of gastrointestinal microbial communities. However, this reliance on fecal materials limits the investigation of microbial dynamics in other locations along the gastrointestinal tract (in situ), and the infrequent availability of fecal samples prevents analysis at finer temporal scales (e.g., hours). In our study...
Source
#1Baoyan Liu (Peking Union Medical College)H-Index: 20
#1Baoyan LiuH-Index: 2
Last. Zhishun LiuH-Index: 2
view all 27 authors...
INTRODUCTION This multicenter, randomized, noninferiority trial compared electroacupuncture with prucalopride for the treatment of severe chronic constipation (SCC). METHODS Participants with SCC (≤ 2 mean weekly complete spontaneous bowel movements [CSBMs]) were randomly assigned to receive either 28-session electroacupuncture over 8 weeks with follow-up without treatment over 24 weeks or prucalopride (2 mg/d before breakfast) over 32 weeks. The primary outcome was the proportion of participant...
4 CitationsSource
#1Amol Sharma (Georgia Regents University)H-Index: 19
#2Satish S.C. Rao (Georgia Regents University)H-Index: 79
Last. Waldman Sa (Thomas Jefferson University)
view all 5 authors...
BACKGROUND Chronic constipation is a common, heterogeneous disorder with multiple symptoms and pathophysiological mechanisms. Patients are often referred to a gastroenterology provider after laxatives fail. However, there is limited knowledge of the spectrum and management of constipation disorders. AIM To discuss the latest understanding of the spectrum of constipation disorders, tools for identifying a pathophysiologic-based diagnosis in the specialist setting, treatment options and the patien...
Source
Background: Non-pharmacologic auxiliary treatments have been considered crucial therapies for treating chronic idiopathic constipation (CIC) during the past decades worldwide. Several treatment patterns are available, but their relative efficacy is obscure because there are no head-to-head randomized controlled trials, especially in children. We conducted this network meta-analysis to evalute the effectiveness of these therapies in improving defecation function based on their direct comparisons ...
Source
#1Gabrio Bassotti (University of Perugia)H-Index: 5
#1Gabrio Bassotti (University of Perugia)H-Index: 69
Last. Gabrio Bassotti (University of Perugia)H-Index: 5
view all 1 authors...
Source